Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
The DOI matches its Crossref record; 186 of the 186 references it cites were found in a registry or an index.
Abstract
Early prediction of clearance mechanisms allows for the rapid progression of drug discovery and development programs, and facilitates risk assessment of the pharmacokinetic variability associated with drug interactions and pharmacogenomics. Here we propose a scientific framework--Extended Clearance Classification System (ECCS)--which can be used to predict the predominant clearance mechanism (rate-determining process) based on physicochemical properties and passive membrane permeability. Compounds are classified as: Class 1A--metabolism as primary systemic clearance mechanism (high permeability acids/zwitterions with molecular weight (MW) ≤400 Da), Class 1B--transporter-mediated hepatic uptake as primary systemic clearance mechanism (high permeability acids/zwitterions with MW >400 Da), Class 2--metabolism as primary clearance mechanism (high permeability bases/neutrals), Class 3A--renal clearance (low permeability acids/zwitterions with MW ≤400 Da), Class 3B--transporter mediated hepatic uptake or renal clearance (low permeability acids/zwitterions with MW >400 Da), and Class 4--renal clearance (low permeability bases/neutrals). The performance of the ECCS framework was validated using 307 compounds with single clearance mechanism contributing to ≥70% of systemic clearance. The apparent permeability across clonal cell line of Madin - Darby canine kidney cells, selected for low endogenous efflux transporter expression, with a cut-off of 5 × 10(-6) cm/s was used for permeability classification, and the ionization (at pH7) was assigned based on calculated pKa. The proposed scheme correctly predicted the rate-determining clearance mechanism to be either metabolism, hepatic uptake or renal for ~92% of total compounds. We discuss the general characteristics of each ECCS class, as well as compare and contrast the framework with the biopharmaceutics classification system (BCS) and the biopharmaceutics drug disposition classification system (BDDCS). Collectively, the ECCS framework is valuable in early prediction of clearance mechanism and can aid in choosing the right preclinical tool kit and strategy for optimizing drug exposure and evaluating clinical risk of pharmacokinetic variability caused by drug interactions and pharmacogenomics.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“On the renal side, the organic cation transporter OCT2 (SLC22A2) together with the multidrug and toxin extrusion proteins MATE1 and MATE2-K mediate active secretion of hydrophilic cations; metformin is the archetype, its clearance being governed by OCT2-mediated uptake and MATE-mediated efflux rather than by glomerular filtration alone, so its disposition tracks transporter activity rather than”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [41]
In the citing paper
“P-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) govern intestinal absorption, biliary excretion, and central nervous system penetration, and their expression, tissue localization, and substrate affinity differ appreciably between rodents, dogs, non-human primates, and humans; body-weight scaling captures none of this, whereas the Extended Clearance Classification Syst”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [41]
In the citing paper
“The Extended Clearance Classification System (ECCS) provides a useful framework for predicting dominant clearance mechanisms and thereby assessing the likely reliability of allometric scaling for a given compound [41].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [41]
In the citing paper
“The case directly catalyzed contemporary requirements for thorough QT studies and hERG screening, the metabolite-aware DDI evaluations that ECCS classification now anchors [41,43,44], and the broader regulatory expectation that compounds with active metabolites or saturable first-pass pathways be characterized across realistic co-medication scenarios rather than in isolation.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [41]
In the citing paper
“The case is now a canonical example of why ECCS classification, transporter-DDI screening, and post-marketing pharmacoepidemiology must be integrated alongside any allometric or PBPK extrapolation [41,43,44,79].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [41]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420
Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995) · Pharmaceutical Research · doi:10.1023/a:1016212804288 · Cited by 5,430
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.019 · Cited by 3,700
Membrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340 · cited 1×
“disposition, therapeutic efficacy, and toxicity [25].”
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043
Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding
Aller, S. G., Yu, J., Ward, A., Weng, Y., Chittaboina, S., Zhuo, R., Harrell, P. M., Trinh, Y. T., Zhang, Q., Urbatsch, I. L., et al. (2009) · Science · doi:10.1126/science.1168750 · Cited by 1,929
Wu, C.-Y., & Benet, L. Z. (2005) · Pharmaceutical Research · doi:10.1007/s11095-004-9004-4 · Cited by 1,401
Impact of OATP transporters on pharmacokinetics
Kalliokoski, A., & Niemi, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00430.x · Cited by 995
The Prediction of Human Pharmacokinetic Parameters from Preclinical and in Vitro Metabolism Data
Obach, R. S., Baxter, J. G., Liston, T. E., Silber, B. M., Jones, B. C., Macintyre, F., Rance, D. J., & Wastall, P. (1997) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36999-x · Cited by 987
Research works printed but not linked: 1
- Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, et al. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol. 2014;78:587–98. · DOI · Paper page
Cited by
BDDCS, the Rule of 5 and drugability
Benet, L. Z., Hosey, C. M., Ursu, O., & Oprea, T. I. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.007 · Cited by 892
In vitro to in vivo extrapolation for high throughput prioritization and decision making
Bell, S. M., Chang, X., Wambaugh, J. F., Allen, D. G., Bartels, M., Brouwer, K. L. R., Casey, W. M., Choksi, N., Ferguson, S. S., Fraczkiewicz, G., et al. (2018) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.11.016 · Cited by 241
Clearance in Drug Design: Miniperspective
Smith, D. A., Beaumont, K., Maurer, T. S., & Di, L. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01263 · Cited by 177
Prantil-Baun, R., Novak, R., Das, D., Somayaji, M. R., Przekwas, A., & Ingber, D. E. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104748 · Cited by 176
OECD (2021) · OECD series on testing and assessment · doi:10.1787/d0de241f-en · Cited by 174
Metadata
- Authors
- Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F.
- Affiliations
- Pfizer (United States) (US)
- Venue
- Pharmaceutical Research
- Published
- 2015-07-09
- Volume
- 32
- Issue
- 12
- Pages
- 3785-3802
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- OpenAlex
- W1894357711
- Cited by
- 334
- References
- 185
- Citations by year
- 2026: 38 · 2025: 35 · 2024: 35 · 2023: 25 · 2022: 34 · 2021: 25 · 2020: 34 · 2019: 32 · 2018: 26 · 2017: 28 · 2016: 19 · 2015: 3
- FWCI
- 26.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Division of Electrical, Communications and Cyber Systems
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- hepatic metabolism, renal clearance, passive membrane permeability, physicochemical properties, MDCK cells, ionization, Biopharmaceutics Classification System, pharmacokinetic variability, drug interactions, pharmacogenomics, drug discovery
- MeSH terms
- Animals, Cell Line, Dogs, Pharmaceutical Preparations, Humans, Kidney, Liver, Metabolic Clearance Rate, Models, Biological, Permeability, Drug Discovery, Renal Elimination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS). https://app.cochat.ai/papers/10.1007/s11095-015-1749-4
- The paper
- Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015). Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS). Pharmaceutical Research. https://doi.org/10.1007/s11095-015-1749-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.